Zydus Receives USFDA Clearance for Ambernath API Facility

Zydus Lifesciences Ltd has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility in Ambernath, Maharashtra. The EIR follows a successful inspection with no observations, confirming compliance with current Good Manufacturing Practices (cGMP). 

USFDA Inspection Results in Zero Observations 

The USFDA conducted the inspection from February 10–14, 2025. Zydus reported that the audit concluded without any observations, reflecting strict adherence to regulatory requirements. The agency classified the outcome as “No Action Indicated” (NAI), the highest compliance rating. 

Reinforcing Commitment to Global Standards 

Zydus highlighted that this favourable outcome reinforces its focus on maintaining quality and compliance across all its facilities worldwide. The Ambernath plant's successful inspection strengthens the company's regulatory standing and manufacturing reliability in the global pharmaceutical supply chain. 

Zydus Lifesciences Share Price 

On May 14, 2025, Zydus Lifesciences share price (NSE: ZYDUSLIFE) opened at ₹903.45, higher than its previous close at ₹901.85. At 3.28 PM, the share price of Zydus Lifesciences was trading at ₹903.90, up by 0.23% on the NSE. 

Also Read: Best Pharma Stocks in May 2025: Neuland Labs, Suven Pharma, Laurus Labs and More - Based on 5-Yr CAGR. 

Conclusion 

The USFDA's clean report for the Ambernath API facility affirms Zydus’ commitment to top-tier manufacturing practices. It also boosts confidence in the company’s ability to meet international compliance benchmarks. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.